NuVision appoints director

Joanna Underhill

Optical tissue therapy firm NuVision Biotherapies has appointed Joanna Underhill as a non-executive director. 

Joanna will play a key role as NuVision expands into community and private optical care in the UK and grows its international footprint, said the company.

The firm produces Omnigen, an amniotic membrane product. This is placed on the eye to aid the natural healing process in ophthalmic conditions and for soft tissue damage. 

It can be directly applied to the ocular surface so no preparation time is required before use. Omnigen is available in 140 UK hospitals, 30 UK private hospitals and seven countries.

NuVision also provides OmniLenz, a specialised bandage contact lens for the application of Omnigen.

Joanna said: “NuVision is at a genuinely exciting period. The science behind the product is exceptional and I’ve been struck by the quality of the team and the opportunities ahead. I am looking forward to bringing my commercial experience to the board and helping NuVision realise its full potential.”

NuVision chair, Roger Teasdale, said: “Jo’s appointment is a significant moment for us. Her depth of experience in building and scaling commercial operations makes her ideally placed to support us as we enter this new chapter.”